Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ME2 | P23368 | 1/20 | 0.61 |
| ▸ | ME1 | P48163 | 1/20 | 0.61 |
| ▸ | ME3 | Q16798 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776281 | 0.96 | CYP2C9 (0.71) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7128759 | 0.94 | POLB (0.72) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL420582 | 0.94 | RAB9A (0.69) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL4051171 | 0.94 | RAB9A (0.69) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL10729724 | 0.92 | KDM4E (0.77) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL2897923 | 0.92 | KDM4E (0.77) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL20236166 | 0.86 | KDM4E (0.70) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL18050103 | 0.86 | KMT2A (0.59) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL2027079 | 0.85 | POLB (0.85) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 | |
| SCHEMBL4526073 | 0.85 | KDM4E (0.68) | CYP2C9CYP2C19POLBKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2697227-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2601190-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | AH USA 42 LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2012142237-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICKS CORPORATION (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | CYP2C9 10/4885CYP2C19 31/4885POLB 1243/4885 |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | CYP2C9 4758/4885CYP2C19 4482/4885POLB 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.